Compounds for treating certain leukemias

MYPI2026002219A0Undetermined Publication Date: 2020-03-18TERNS PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026002219
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-08-21
Filing Date
2019-09-17
Publication Date
2020-03-18
Patent Text Reader

Abstract

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and / or symptomology of the disease. No Suitable Fig.
Need to check novelty before this filing date? Find Prior Art